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Cystic ﬁbrosis (CF) is the most common autosomal genetic recessive disease caused by mutations of gene encoding for the cystic
ﬁbrosis transmembrane conductance regulator. Patients with CF display a wide spectrum of symptoms, the most severe being
chronic lung infection and inﬂammation, which lead to onset of cystic ﬁbrosis lung disease. Several studies indicate that
sphingolipids play a regulatory role in airway inﬂammation. The inhibition and downregulation of GBA2, the enzyme
catabolizing glucosylceramide to ceramide, are associated with a signiﬁcant reduction of IL-8 production in CF bronchial
epithelial cells. Herein, we demonstrate that GBA2 plays a role in the proinﬂammatory state characterizing CF cells. We also
report for the ﬁrst time that Pseudomonas aeruginosa infection causes a recruitment of plasma membrane-associated
glycosphingolipid hydrolases into lipid rafts of CuFi-1-infected cells. This reorganization of cell membrane may be responsible
for activation of a signaling cascade, culminating in aberrant inﬂammatory response in CF bronchial epithelial cells upon
bacterial infection. Taken together, the presented data further support the role of sphingolipids and their metabolic enzymes in
controlling the inﬂammatory response in CF.
1. Introduction
Cystic ﬁbrosis (CF) is the most common autosomal genetic
recessive disease in Caucasian population, aﬀecting approxi-
mately 1 in 2500–4000 newborns [1]. CF is caused by muta-
tions of the gene encoding for cystic ﬁbrosis transmembrane
conductance regulator (CFTR).
The main phenotype of CF is characterized by accumula-
tion of viscous mucus at the epithelial surface of diﬀerent
organs such as the lungs, pancreas, gut, and testes, often
resulting in inﬂammation and organ failure. CF patients
usually die prematurely due to onset of cystic ﬁbrosis lung
disease, originating from chronic lung infection and inﬂam-
mation [1]. The hallmarks of increased inﬂammation in CF
are high levels of interleukin (IL)-1β, IL-6, IL-8, and tumor
necrosis factor-α (TNFα).
IL-8 is abundantly expressed at sites of chronic infection
and its expression seems correlated with generation of
neutrophil- (PMN-) rich exudates in the lungs of CF patients
[2–5]. The IL-8 cascademay hence represent a key therapeutic
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target for mitigating CF lung inﬂammation. Several factors
contribute to the severity of CF inﬂammation. Among these,
an increasing number of studies highlight that sphingolipids
(SLs) play an important regulatory role in CF pulmonary
infection and inﬂammation [6–14].
SLs are predominantly present in the external leaﬂet of
the plasma membrane. These amphipathic molecules are
characterized by a hydrophobic moiety (ceramide), inserted
into the cellular lipid bilayer, and a hydrophilic group
of diﬀerent complexity protruding toward extracellular
environment [15].
SLs are not merely structural components of biological
membranes, but play other important roles in regulation of
cell physiology [16]. At the plasma membrane (PM), SLs,
together with cholesterol, saturated phospholipids, and a
speciﬁc pool of proteins, form macromolecular complexes
that are conventionally deﬁned lipid rafts [17, 18].
Several studies have depicted membrane rafts as
dynamic nanoscale domains playing an important role in
cell signal transduction [19]. Interestingly, modiﬁcations of
lipid raft SL composition are associated with many cellular
processes, such as neuronal diﬀerentiation and senescence,
insulin resistance, and inﬂammatory response to bacterial
infections [8, 20, 21].
Several processes concur to determine the PM SL pattern
and content, that is, neobiosynthesis in the endoplasmic
reticulum and Golgi apparatus and catabolism in lysosomes.
Recent reports also suggest that the enzymes involved in the
SL metabolism are also present within the cell PM [22].
In particular, the presence of diﬀerent hydrolases
involved in the in situ reorganization of the PM SL compo-
sition has been described at the cell surface of several cell
lines. Sphingomyelinases (SMase), β-galactosidase (β-Gal),
β-hexosaminidase (β-Hex), sialidase Neu3, β-glucocerebro-
sidase GBA1, and the nonlysosomal β-glucosylceramidase
GBA2 have already been identiﬁed [23, 24]. These PM-
associated hydrolases seem to play an active role in the
inﬂammatory response of CF bronchial epithelial cells
subjected to P. aeruginosa infection, although a direct corre-
lation has not been reported so far [25].
Genetic silencing and pharmacological inhibition of
acid sphingomyelinase reduce Cer levels, thus resulting
in decreased inﬂammatory response to P. aeruginosa
infection [26].
On the other hand, the catabolism of complex glyco-
sphingolipids (GSL) at PM level seems to play an important
role in the proinﬂammatory state of CF and in inﬂammation
caused by P. aeruginosa infection [25].
Of considerable interest is the nonlysosomal beta-
glucosylceramidase GBA2, an enzyme involved in the ﬁnal
hydrolysis of glucosylceramide (GlcCer) to ceramide at the
cell surface. Recent data show that inhibition of GBA2 with
miglustat reduces the inﬂammatory response in CF bronchial
epithelial cells infected by P. aeruginosa [25].
Moreover, GBA2 knockdown in noninfected cells induces
a reduction of IL-8 basal level and, therefore, of the intrinsic
proinﬂammatory state [25].
Nevertheless, themechanistic linkbetween involvementof
GBA2 or other PM-associated hydrolases and inﬂammatory
response in CF is unknown. We herein report data
supporting the role of GBA2 in the inﬂammatory response
to P. aeruginosa infection.We also describe that P. aeruginosa
infection causes a reorganization of the lipid rafts isolated
from CF bronchial epithelial cells.
2. Materials and Methods
2.1. Cell Culture. The CuFi-1 and NuLi-1 cell lines were a
generous gift of A. Klingelhuts, Pkarp, and J. Zbaner, Univer-
sity of Iowa, Iowa City [27], and were cultured as previously
described [25]. Brieﬂy, the cells were cultured as monolayer
in a humidiﬁed atmosphere at 37°C and 5% CO2 in ﬂasks
precoated with collagen (collagen IV from human placenta,
Sigma-Aldrich) in bronchial epithelial growth medium
(BEGM by Lonza; singleQuot Kit Lonza).
2.2. Generation of CuFi-1 and NuLi-1 Cell Lines
Overexpressing GBA2-GFP. CuFi-1 and NuLi-1 cell lines
overexpressing GBA2 tagged with GFP were generated by
3rd generation lentiviral particles carrying a lentiviral vector
coding for GBA2-GFP fusion protein (pLenti-GBA2-GFP). A
lentiviral vector containing only GFP (pLenty-GFP) was used
to generate mock cells. Viral particles were generated by
transfecting 293FT cells with 3μg of pLenti-GBA2-GFP or
pLenti-GFP vectors and 9μg of packaging vector mix (coding
forGag, Pol Tat, Rev, andVSVG), using Lipofectamine™ 2000
Reagent (Invitrogen).
Supernatant media were collected 48 h after transfection,
ﬁltered through a 0.4μm membrane, and used to transduce
cells according to manufactures instructions.
CuFi-1 and NuLi-1 cells were infected with 1ml of each
lentivirus stock. After 1 day, the medium was replaced with
fresh medium containing the speciﬁc antibiotic to select
positive clones. To obtain constitutive clones, transduced
cells were identiﬁed with 5μg/ml of puromycin. After 3 weeks
of selection, colonies were separated and expanded. The cells
were cultured as monolayer in a humidiﬁed atmosphere at
37°C and 5% CO2 in ﬂasks, precoated with collagen (collagen
IV fromhumanplacenta, Sigma-Aldrich) and using bronchial
epithelial growth medium (BEGM by Lonza; singleQuot Kit
Lonza) in the presence of 1μg/ml of puromycin.
Clones obtained were morphologically analyzed for
GBA2 tagged with GFP or GFP expression by confocal
microscopy after ﬁxing cells with paraformaldehyde (2% in
PBS) for 20min. The expression of GBA2 mRNA was
measured by real-time qRT-PCR as described [28, 29].
2.3. Bacterial Strain. For infection experiments, heat-killed
P. aeruginosa strain PAO1, kindly provided by A. Prince
(Columbia University, New York), was used.
PAO1 was grown in a Trypticase soy broth (TSB) or agar
(TSA), as described by Dechecchi and colleagues [30]. The
organism was killed by heating to 65°C for 30min [25].
2.4. Bacterial Infection and Evaluation of IL-8 Secretion. Cells
were infected for 4 h with PAO1 (100CFU/cells). Quantita-
tive measurement of IL-8 protein release in the cell medium
was evaluated using human IL-8 instant ELISA kit (Bender
MedSystems, Wien, Austria). The expression of IL-8 mRNA
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was measured by real-time qRT-PCR as previously
described [29].
2.5. Cell Sphingolipid Labelling with [1-3H]-Sphingosine.
[1-3H]-sphingosine was administered as tracer at nonbioac-
tive concentration for 2 h (pulse), to allow steady-state
metabolic labelling of all cell SLs [31]. Brieﬂy, [1-3H]-
sphingosine dissolved in methanol was transferred into a
sterile glass tube, dried under a nitrogen stream and then
solubilized in an appropriate volume of a prewarmed (37°C)
medium (BEGM) to obtain a ﬁnal concentration of 0.3 nM.
The correct solubilisation was veriﬁed by measuring the
radioactivity associated with an aliquot of a medium by
beta-counter (PerkinElmer). After 2 h of incubation (pulse),
the medium was removed and the cells were incubated
for 48h (chase) in a fresh culture medium without radio-
active sphingosine. After chase, cells were collected and
used to perform analysis of radioactive lipids or detergent-
resistant membrane (DRM) preparation.
2.6. Isolation of Detergent-Resistant Membrane Fractions.
DRM were prepared by ultracentrifugation on discontinuous
sucrose gradient of cells subjected to homogenization with
1% Triton X-100, as previously described [32]. Brieﬂy, cells
were mechanically harvested in PBS and centrifuged at
270×g for 10min. Cell pellet was lysed in 1.2ml of 1% Triton
X-100 in TNEV buﬀer (TrisHCl 10mM, NaCl 150mM,
EDTA 5mM, pH7.5) in the presence of 1mM Na3VO4,
1mM PMSF, and 75mU/ml aprotinin and homogenized
with tight Dounce.
Cell lysate (2mg of cell protein/ml) was centrifuged for
5min at 1300×g to remove nuclei and cellular debris, to
obtain postnuclear supernatant (PNS).
A volume of 1ml of PNS was mixed with 1ml of 85%
sucrose (w/v) in TNEV buﬀer containing 1mM Na3VO4,
placed at the bottom of a discontinuous sucrose gradient
(30% and 5%), and centrifuged for 17 h at 200,000×g at 4°C.
After ultracentrifugation, 11 fractions were collected.
The light-scattering band, corresponding to the DRM frac-
tion, was located at the interface between 5% and 30%
sucrose corresponding to fraction 4 or 5. Equal amounts
of low-density fractions (4 and 5) were mixed to obtain
DRM fraction, whereas equal amounts of high-density
fractions (10 and 11) were mixed to obtain the HD fraction
used for lipid analyses and hydrolase assays. The entire proce-
dure was performed at 0–4°C on ice immersion.
2.7. Sphingolipid Analysis. Cell lysates or DRM and HD frac-
tions were dialyzed, lyophilized, and subjected to lipid extrac-
tion and SL analyses. Total lipids were extracted with CHCl3/
CH3OH/H2O 20 : 10 : 1 by vol, followed by a second extrac-
tion with CHCl3/CH3OH 2 : 1 by vol. The total lipid extracts
were subjected to a two-phase partitioning by adding 20%
water to lipid extract. The radioactivity associated with total
lipid extract, aqueous, and organic phases was evaluated by
liquid scintillation, using a beta-counter system (PerkinEl-
mer). Organic phases were subjected to alkali treatment to
remove glycerophospholipids, as described elsewhere [33].
[3H]SLs of total extracts and organic phases were sepa-
rated by high-performance thin layer chromatography
(HPTLC), using the solvent system CHCl3/CH3OH/H2O
110 : 40 : 6 by vol, and those of aqueous phases with CHCl3/
CH3OH/0.2% aqueous CaCl2, 50 : 42 : 11 by vol. [
3H]-SLs
were identiﬁed by digital autoradiography using the TRacer
system (Biospace Lab) and quantiﬁed with M3vision soft-
ware. The lipid identiﬁcation was performed using puriﬁed
radioactive standards [33].
2.8. Enzymatic Activity Associated with the Cell Plasma
Membrane. PM-associated activities of β-galactosidase
(β-Gal), β-glucosidase GBA1, β-glucosidase GBA2, and
β-hexosaminidase (β-Hex) were assessed in living cells,
plated in 96-well microplates at a density of 20,000 cells/
well, by a high-throughput cell live-based assay, as previ-
ously described [34, 35].
In order to distinguish between GBA1 and GBA2 activity,
cells were preincubated for 30min at room temperature in
DMEM-F12 containing 5nM AMP-dNM (adamantane-
pentyl-dNM; N-(5-adamantane-1-yl-methoxy-pentyl) deox-
ynojirimycin) a speciﬁc inhibitor of GBA2 or 1mM
CBE (conduritol-B-epoxide) (Sigma) a speciﬁc inhibitor of
GBA1 [36].
β-Gal, β-Hex, and β-Glc activities were assayed using
the artiﬁcial substrates 4-methylumbelliferyl-β-D-galacto-
pyranoside (MUB-Gal), 4-methylumbelliferyl-N-acetyl-β-
D-glucosaminide (MUG), and 4-methylumbelliferyl-β-D-
glucopyranoside (MUB-Glc) solubilized in DMEM-F12
without phenol red at pH6, at ﬁnal concentrations of
250μM, 2mM, and 6mM, respectively.
Aliquots of medium (10μl) were analyzed at diﬀerent
time points with a ﬂuorimeter in a microplate reader (Victor,
PerkinElmer) (MUB: λex: 355 nm/λem: 460nm), after add-
ing 190μl of 0.25M glycine, pH 10.7.
Standard free MUB was used to construct a calibration
curve and to quantify substrate hydrolysis. The enzymatic
activity was expressed as pmoles of product/106 cells/h.
The experimental design was made considering all the
controls in terms of both cell line used and internal control
for the experimental procedures. In particular, this method
is based on the observation that the ﬂuorigenic substrates
commonly used for the in vitro assay of glycohydrolase
activities are not taken up by living cells. To be sure that
the substrate hydrolysis occurs only upon the activity of
PM enzymes, a series of control were performed. In the used
experimental condition, we did not observe any ﬂuorescence
associated with cells conﬁrming that the substrates were not
able to cross the cell membrane. Moreover, we veriﬁed that
the artiﬁcial substrates did not undergo spontaneous hydro-
lysis or hydrolysis driven by secreted enzymes. Thus, their
hydrolysis under these experimental conditions is due exclu-
sively to the PM-associated enzymatic activities.
2.9. Enzymatic Activities Associated with Cell Lysate and
Sucrose Gradient Fractions. The enzymatic activities of
β-galactosidase (β-Gal), β-glucosidase GBA1, β-glucosi-
dase GBA2, β-hexosaminidase (β-Hex), and sphingomyeli-
nases (SMase) were determined in the total cell lysates using
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ﬂuorigenic substrates, as previously described with fewmodi-
ﬁcations [37, 38].
Brieﬂy, cells were washed twice with PBS, harvested, and
suspended in water in the presence of a protease inhibitor
cocktail (Sigma-Aldrich). Total cell proteins were evaluated
by DC™ protein assay (Bio-Rad), performed according to
manufacturer instructions.
Equal amounts of cell proteins were transferred into a
96-well microplate and the assay was performed 3-fold in rep-
licate. MUB-Glc was solubilized in McIlvaine buﬀer (pH6) at
concentration of 6mM. MUB-Gal, MUG, and H-MUB-PC
(used for SMase assay) were solubilized in McIlvaine buﬀer
(pH5.2) at concentrations of 500μM, 1mM, and 500μM,
respectively.
In order to distinguish between GBA1 and GBA2
activity, cells were preincubated for 30min at room tem-
perature in McIlvaine buﬀer (pH6) with 5nM AMP-dNM
(adamantane-pentyl-dNM; N-(5-adamantane-1-yl-meth-
oxy-pentyl) deoxynojirimycin) a speciﬁc inhibitor of GBA2
or 1mM CBE (conduritol-B-epoxide) (Sigma) a speciﬁc
inhibitor of GBA1.
The reaction mixtures were incubated at 37°C under
gentle shaking. After diﬀerent times of incubation, 10μl of
the reaction mixtures was transferred to a 96-black-well
microplate adding 190μl of glycine (0.25M, pH10.7). In
the case of H-MUB-PC, 0.3% of Triton X-100 were added
to glycine solution. Fluorescence was detected at diﬀerent
time points with a Victor microplate reader (PerkinElmer).
Standard free MUB and H-MUB were used to construct
calibration curves for quantifying substrate hydrolysis. The
enzymatic activity was expressed as pmoles of product/mg
protein/h. The enzymatic activity associated with sucrose
gradient fractions was expressed as pmoles of product/vol-
ume of fraction/h. Due to the presence of Triton X-100 deter-
gent, we could not detect GBA2 activity associated with
gradient fractions.
2.10. Statistical Analysis. All the experiments were performed
in triplicate otherwise diﬀerently indicated, and statistical
signiﬁcance was determined by Student-Neumann-Keuls
post hoc test (comparison between two groups) and by
one-way or two-way ANOVA (followed by Turkey or Dun-
nett Neueman-Keuls on Bonferroni post test) for more than
two groups, with statistical signiﬁcance set at p < 0 05, using
GraphPad Prism 5.
3. Results
3.1. PM-Associated Glycohydrolases Are Involved in
Controlling the Proinﬂammatory State in CF. We previously
reported an association between GBA2 silencing and reduc-
tion of IL-8 expression in CF bronchial epithelial cells [25].
To date, it is accepted that the accumulation of Cer correlates
with the intrinsic proinﬂammatory state of CF and the age-
dependent hypersusceptibility to infections [8]. Interestingly,
this inﬂammatory state is a feature of CuFi-1 cells, a widely
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Figure 1: Sphingolipid composition of CuFi-1 and NuLi-1 cells. (a) HPTLC of radioactive sphingolipids obtained from total lipid extract of
CuFi-1 and NuLi-1 cells. (b) Semiquantitative graph of sphingolipids species. The sphingolipids are represented as percentage of radioactivity.
Cer: ceramide; GlcCer: glucosylceramide; PE: phosphatidylethanolamine; SM: sphingomyelin. The sphingolipid composition of CuFi-1
and NuLi-1 cells was evaluated performing three diﬀerent experiments and for each experiment, one HPTLC was performed. ∗p < 0 05
versus NuLi-1.
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used CF bronchial epithelial cell model that shows a higher
basal IL-8 secretion compared to non-CF bronchial epithelial
cells, NuLi-1.
The analysis of SL composition of both cell lines
(Figure 1) showed that CuFi-1 cells have an increased content
of Cer and GlcCer, followed by a slight reduction of ganglio-
side GM3 compared to NuLi-1 cells.
We measured the activity of the main hydrolases
involved in SL catabolism, observing that the activity of all
enzymes tested was higher in NuLi-1 compared to CuFi-1
cells (Figure 2). Interestingly, opposite results were obtained
by assay of hydrolases activity measured at PM level.
Figure 3 shows that CuFi-1 cells have a twofold increase in
the activity of hydrolases present at cell PM such as GBA1,
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β-Gal, and β-Hex, compared to NuLi-1 cells. Notably, the
activity of GBA2 was 4-fold higher in CuFi-1 compared to
NuLi-1 cells. This data is consistent with our previous results
[25] on the role of GBA2 in inﬂammatory response. To fur-
ther support these ﬁndings, we stably overexpressed GBA2
in CuFi-1 cells as GFP fusion protein. As control cells, we
generated mock cell lines overexpressing GFP.
After 3 weeks, several clones were morphologically ana-
lyzed by confocal microscopy, to detect GFP-tagged GBA2.
As shown in Figure 4(a), GBA2-overexpressing cells (CuFi-
1-GBA2) are characterized by a clear signal at the cell surface
compared to mock cells, although a diﬀuse intracellular
ﬂuorescence was observed.
The activity of GBA2 in mock (CuFi-1 mock) and in
GBA2-overexpressing (CuFi-1-GBA2) cells was measured
both in total cell lysate and at the PM. As shown in
Figure 4(b), GBA2-overexpressing cells are characterized by
increased GBA2 activity, 300-fold and 130-fold higher in
total cell lysate and cell PM, respectively.
The eﬀect of GBA2 overexpression on the SL pattern
was analyzed after metabolic labeling at the steady state,
with the radioactive precursor [1-3H]-sphingosine. GBA2-
overexpressing CuFi-1 cells are characterized by a strong
decrease of GSL such as GM3 and GlcCer, followed by
increased Cer and SM content (Figure 4(c)). Interestingly,
higher GBA2 activity induces a forced catabolism of GM3
and GlcCer to ceramide, which can be converted to SM,
as previously suggested [39].
Several lines of evidence suggest that cells react to activity
variations of one of the enzymes of SL metabolism by modi-
fying the function of other enzymes involved in the same
catabolic pathway [28]. For this reason, we measured the
activity of the main cell hydrolases.
Our results show that overexpression of GBA2 in CuFi-1
cells causes an increase of GBA1 and β-Gal activity in total
cell lysate. In mock and parental CuFi-1 cells, GBA1 activity
is 3857± 635 pmoles/mg/h, increasing to 10,408± 690
pmoles/mg/h in CuFi-1-GBA2, whereas β-Gal increased in
CuFi-1-GBA2 compared to CuFi-1 or mock cells (Figure 5).
We also evaluated the activity of GBA1, β-Gal, and β-Hex
at the PM of living mock- and GBA2-overexpressing cells.
As shown in Figure 5, a slight increase of GBA1 was observed
compared to mock cells, whereas the PM-associated β-Gal
increased more than 50-fold in CuFi-1-GBA2 cells compared
to mock or CuFi-1 cells.
Signiﬁcant diﬀerences in total β-Gal and PM-associated
β-Hex were found between CuFi-1 and mock cells, probably
caused by the diﬀerent passages in culture due to the trans-
fection process. Unfortunately, the CuFi-1 cell line is charac-
terized by an undetectable SMase activity at the PM level
(data not shown).
Since the silencing of GBA2 causes a reduction of IL-8 in
the proinﬂammatory state and in the inﬂammatory response
to P. aeruginosa, we also investigated the eﬀect of GBA2 over-
expression by measuring IL-8 protein secretion in GBA2-
overexpressing CuFi-1 cells compared to CuFi-1 cells.
Figure 6 shows that GBA2-overexpressing cells are character-
ized by a signiﬁcant increase of IL-8 secretion in basal condi-
tion as well as in response to P. aeruginosa infection. We
analyzed the eﬀect of GBA2 overexpression in terms of IL-
8 production also in NuLi-1 cells. We evaluated the IL-8
production in the basal status of NuLi-1 cells, as well as,
after Pseudomonas aeruginosa infection.
As shown in Figure 7, the results obtained indicate that
the basal expression of IL-8 of NuLi-GBA2-overexpressing
cells is not signiﬁcantly diﬀerent compared to basal IL-8 of
NuLi-mock cells. This suggests that the overexpression of
GBA2 in non-CF cells does not aﬀect the basal expression
of IL-8. No eﬀect was found also in NuLi-GBA2 subjected
to P. aeruginosa infection.
These data further support the role of GBA2 in the
aberrant inﬂammatory state occurring in CF bronchial
epithelial cells.
3.2. P. aeruginosa Infection Causes a Reorganization in the
DRM Isolated from CF Bronchial Epithelial Cells. We previ-
ously showed that P. aeruginosa triggers signiﬁcant changes
in SL composition, generating an increase in Cer content
[25]. As suggested by others, these alterations seem attribut-
able to activation of SL catabolic pathways [10, 40].
We hence investigated the eﬀect of P. aeruginosa
infection on enzymatic activity of SMase and on the main
glycohydrolases involved in regulation of Cer content
(i.e., GBA1, GBA2, β-Gal, and β-Hex) in CuFi-1 cells.
We ﬁrst infected CuFi-1 cells with heat-killed P. aeru-
ginosa strain PAO1 for 4 h and then measured hydrolases
activity in total cell lysate. As shown in Figure 8, no signif-
icant diﬀerence was observed in the activity of total cell
hydrolases between infected and noninfected CuFi-1 cells.
We then quantiﬁed GBA1, GBA2, β-Gal, and β-Hex
activities at cell surface of CuFi-1 cells under identical
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Figure 6: Eﬀect of GBA2 overexpression on inﬂammatory response
of CuFi-1 cells. Quantitative measurement of IL-8 protein release in
the cell medium of CuFi-1 and CuFi-1-GBA2 cells infected or not
with PAO1 for 4 h (100CFU/cell). Data are mean± SEM of three
independent experiments performed in duplicate. Comparison
between groups were done by Student’s t-test. ∗p < 0 0001 versus
CuFi-1 cells, °p < 0 01 versus CuFi-1 cells versus CuFi-1 cells
infected, #p < 0 0001 versus CuFi-1 cells infected.
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experimental conditions. Neither in this case we could ﬁnd
signiﬁcant diﬀerences between infected and noninfected
CuFi-1 cells (Figure 9).
Notably, the assay used for measuring hydrolase activity
at PM level allows measuring the enzymatic activity of the
entire cell surface, but does not actually reﬂect the activity
of a speciﬁc PM area.
SLs form speciﬁc membrane domains within PM, which
are called lipid rafts, and are involved in activation and regu-
lation of diﬀerent intracellular pathways. In order to study
the involvement of these membrane domains in PAO1
inﬂammatory response, we labeled cell SLs at the steady state
with [1-3H]-sphingosine. We isolated lipid rafts from
infected and noninfected cells as the detergent-resistant
membrane (DRM), according to the procedure thoughtfully
described in “Materials and Methods”.
For isolation of DRM fraction, the same amount of cell
proteins from infected or noninfected cells, lysed with 1%
Triton X-100, was loaded on a discontinuous sucrose
gradient. After ultracentrifugation, eleven fractions were
collected and the radioactivity associated with each of them
was then assayed.
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Figure 7: Eﬀect of GBA2 overexpression on inﬂammatory response of NuLi-1 cells. (a) IL-8 mRNA expression at basal level of NuLi-1-GBA2
cells versus NuLi-1 mock cells. (b) IL-8 mRNA expression after Pseudomonas aeruginosa infection in NuLi-1-GBA2 cells versus NuLi-1 mock
cells.
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Figure 8: Eﬀect of P. aeruginosa infection on the activity of total cell hydrolases of CuFi-1 cells. The measurements of the hydrolases activity
were conducted on cell lysate by an in vitro enzymatic assay using artiﬁcial ﬂuorigenic substrates. Before the assay, cells were infected or not
for 4 hours with PAO1. The enzymatic activities are expressed as pmoles of product/mg of proteins per hour.
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As expected, an enrichment in radioactivity was observed
in low-density fractions 4 and 5, thus suggesting SL enrich-
ment. The remaining radioactivity was present in high-
density (HD) fractions.
Interestingly, PAO1 infection causes a 20% increase of
radioactivity in the DRM of infected CuFi-1 cells (Figure 10).
In order to evaluate possible lysosomal contaminations,
we performed an analysis of a lysosomal marker on gradient
fractions. We performed an immunoblotting using an
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Figure 9: Eﬀect of P. aeruginosa infection on plasma membrane hydrolases of CuFi-1 cells. The measurements of the plasma membrane
hydrolase activity were conducted on living cells, using artiﬁcial ﬂuorigenic substrates. Before the assay, cells were infected or not for 4
hours with PAO1. The enzymatic activities are expressed as pmoles of product/106 per hour.
0 1 2 3 4 5 6 7 8 9 10 11
0
50000
100000
150000
CTRL
PAO1
Fractions
(d
pm
)
Figure 10: Radioactivity distribution within gradient fractions of CuFi-1 cells infected or not with P. aeruginosa. Cell sphingolipids were
labeled at the steady state with [1-3H]-sphingosine. We isolated the lipid rafts from infected and noninfected cells as the detergent-
resistant membrane (DRM) following the procedure described in details in “Materials and Methods”. After ultracentrifugation, we
collected eleven fractions and we measured the radioactivity associated to each of them.
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Figure 11: Immunoblotting against the lysosomal marker Lamp-1.
Immunoblotting analyses against Lamp-1 performed on
postnuclear supernatant (PNS), detergent-resistant membrane
(DRM) fraction, fraction number 8 (#8), and high-density (HD)
fraction from CuFi infected or not with P. aeruginosa.
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Figure 12: Sphingolipids composition of DRM and HD fractions obtained from CuFi-1 cells, infected or not with P. aeruginosa. (a) HPTLC
of radioactive lipids contained in the total lipid extract, and aqueous phase obtained from detergent-resistant membrane (DRM) and high-
density (HD) fraction of CuFi-1 cells, infected or not with PAO-1 (left). Semiquantitative graph of ganglioside composition of DRM from
both infected and noninfected CuFi-1 cells. Data are expressed as radioactivity associated with the aqueous phase (right). (b) HPTLC of
radioactive lipids contained in the alkali-treated organic phase obtained from the detergent-resistant membrane (DRM) and high-density
(HD) fraction of CuFi-1 cells, infected or not with PAO-1 (left). Semiquantitative graph of sphingolipid species contained in the organic
phase of DRM and HD fraction obtained from both infected and noninfected CuFi-1 cells. Data are expressed as radioactivity associated
with the organic phase. The same amount of fraction were loaded on HPTLC. Cer: ceramide; GlcCer: glucosylceramide; PE:
phosphatidylethanolamine; Gb3: globotriaosylceramide; SM: sphingomyelin. ∗p < 0 05 versus CTRL.
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antibody against the lysosomal marker Lamp-1 on DRM and
HD fractions. As reported in Figure 11, no signals are detect-
able in DRM fraction, whereas a marked spot is associated
with HD and PNS fraction.
As a further step, we analyzed the SL composition of
DRM and HD of CuFi-1 cells, infected or not with PAO1.
Interestingly, we found a slightly decreased radioactivity in
the aqueous phase derived from DRM and HD fraction of
infected cells compared to noninfected cells (Figure 12(a)).
The lower radioactivity in the aqueous phase derived
from DRM of infected cells could be attributed to ganglio-
sides GM3 and GM1 (Figure 12(a)). The analysis of nonpolar
SLs of DRM fraction of CuFi-1 cells infected with PAO1
showed a 22–27% increase of ceramide and a slight increase
of Gb3, SM, and GlcCer (Figure 12(b)). The organic phase
of HD fraction of CuFi-1-infected cells is only characterized
by a modest increased GlcCer content compared to nonin-
fected cells (Figure 12(b)).
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Figure 13: Eﬀect of P. aeruginosa infection on hydrolases activity associates with DRM and HD fractions. The measurements of the
hydrolases activity were conducted on DRM (a) and HD (b) fraction obtained from CuFi-1 cells infected or not with PAO-1, using an
in vitro assay based on artiﬁcial ﬂuorigenic substrates. The enzymatic activity was evaluated on the same volume of fraction and expressed
as pmoles of product/total volume of fraction per hour. ∗p < 0 0001 versus CTRL.
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Considering the diﬀerences in the SL pattern of gradient
fractions, especially of DRM of infected and noninfected
cells, we hence investigated the eﬀect of infection on
hydrolases in DRM fraction. Our results show signiﬁ-
cantly increased activities of DRM upon infection with
PAO1 (Figure 13).
This data demonstrates that GBA1 and SMase activ-
ities are more than doubly increased in DRM derived
from infected cells, whilst β-Gal and β-Hex increase
over 3-fold. We measured the same hydrolases activity
in HD fraction, but we did not ﬁnd a signiﬁcant diﬀer-
ence in enzymatic activity of infected and noninfected
cells (Figure 13).
4. Discussion
Several studies in diﬀerent CF models strongly support the
existence of a relationship between SLs, inﬂammatory
response, and susceptibility to bacterial infection. In particu-
lar, increased PM Cer levels in CF bronchi seem to be corre-
lated with the proinﬂammatory status characterizing CF lung
disease [14].
In accordance with previous studies, we found that
CuFi-1 and NuLi-1 cells are characterized by a SL com-
position recalling the features found in lung tissue of
CF and non-CF patients [14]. An important diﬀerence
was observed in ganglioside composition between CuFi-1
and NuLi-1 cells. The main ganglioside of CuFi-1 cells
is GM3, whereas GM1 predominates in NuLi-1 cells.
The diﬀerences in ganglioside composition between CF
and not-CF cell lines are in line with evidence reported
by Itokazu and colleagues [41], who described a direct
correlation between ganglioside GM1 levels at PM and
CFTR expression. In addition, as observed in CF lung tis-
sue [11], CuFi-1 cells are characterized by a high content
of Cer.
The activity of the PM glycohydrolases is another impor-
tant diﬀerence between these two cell lines, since CuFi-1 cells
are seemingly being characterized by higher activity of PM
glycohydrolases compared to NuLi-1 cells.
Hydrolysis of the SLs directly triggered at PM by PM
hydrolases may play an important role in regulating several
physiological and pathological cellular processes [23].
Interestingly, part of Cer in bronchial epithelial cells is
produced in response to P. aeruginosa infection through
SM catabolism at PM by the acid-sphingomyelinase [42].
Conversely, bioactive Cer can be produced by action of
PM glycohydrolases through GSL degradation at the cell
surface, as shown in human ﬁbroblasts [35, 43] and cancer
cells [44]. However, limited information is available on the
involvement of these enzymes in CF lung disease. Among
PM glycohydrolases, nonlysosomal β-glucosylceramidase
GBA2 plays a crucial role in the inﬂammatory response
in CF bronchial epithelial cells.
GBA2 is an important player in the regulation of SL
homeostasis at PM and is also a key enzyme in production
of Cer at this site. Interestingly, we found that the main dif-
ference in PM activities between CuFi-1 and NuLi-1 cells is
attributable to GBA2, which was 4-fold higher at the cell sur-
face of CF bronchial epithelial cells.
Our recent data showed that pharmacological inhibition
of GBA2, along with downregulation of its expression, is
associated with signiﬁcant reduction of inﬂammatory
response to P. aeruginosa infection. Moreover, knocking
down of GBA2 reduced the intrinsic proinﬂammatory state
of CF epithelial bronchial cells [25].
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Figure 14: Graphical representation of the eﬀect of P. aeruginosa infection on CF bronchial epithelial cells.
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To further support the role of GBA2 in CF inﬂamma-
tion, we overexpressed this enzyme tagged with GFP at
C-terminal in CuFi-1 cells. GBA2-overexpressing cells were
characterized by a strong increase of PM β-gal, which is
suggestive of the existence of a crosstalk among diﬀerent
catabolic enzymes.
As expected, GBA2-overexpressing cells were character-
ized by a diﬀerent SL proﬁle, characterized by a marked
decrease of GSL (e.g., GM3, Gb3, and GlcCer), followed by
increased Cer and SM content. The lower increase of Cer
level may be due to the formation of a complex between
GBA2 and sphingomyelin synthase 2, which converts Cer
to SM, as earlier suggested [39].
Since GBA2 is present within two diﬀerent cellular com-
partments (i.e., PM and ER-Golgi), data on its eﬀects on the
SL pattern allow postulating two diﬀerent hypothesis:
(1) The increased PM-GBA2 activity, along with β-Gal,
induces a catabolic unbalance which is not oﬀset by
de novo biosynthesis of complex GSL.
(2) The increased GBA2 activity in ER/Golgi reduces
GlcCer values, thus decreasing substrate availability
for de novo synthesis of GSL complex.
These speculations need further studies that we plan to
address in the near future.
As regards the inﬂammatory state of CuFi-1 cells
overexpressing GBA2, an increased IL-8 secretion was
found to be associated with overexpression of GBA2.
These results support the role of GBA2 in the activation
of inﬂammatory response in CF. However, GBA2 is not
the only SL-hydrolytic enzyme at the cell surface. Several
enzymes involved in catabolism of complex GSL at PM
have been identiﬁed, including GBA1, β-Gal, β-Hex, sia-
lidase Neu3, and SMase. In particular, β-Hex and β-Gal
were found in the lipid rafts of Jurkat T-lymphocytes,
where they are seemingly involved in local reorganiza-
tion of these membrane areas. The involvement of this
machinery has never been described so far in inﬂammatory
response of CF.
The ﬁrst evidence that we obtained was a clear eﬀect of
bacterial infection on DRM organization, since the DRM of
infected cells was associated with increased SL content
compared to uninfected cells.
The SL composition of DRM in infected cells is charac-
terized by a reduction of GSL, combined with an increase
in simple SL, including Cer.
This is evocative of a local activation of catabolic machin-
ery. Interestingly, the activities of β-Gal, GBA1, β-Hex, and
SMase were found to be increased in DRM isolated from
infected cells.
Taken together, these results suggest that P. aeruginosa
infection causes an important rearrangement of the PM
structure and composition in CF cells (Figure 14). This
bacterial infection would probably lead to recruitment of
glycohydrolases in speciﬁc membrane domains, enriched
in SLs. The concomitant presence of glycohydrolases and
their substrates induces signiﬁcant changes of SL composi-
tion, which together with Cer organize speciﬁc platforms
involved in activation of inﬂammatory response. These
ﬁndings open new challenges for investigating the signaling
cascade triggered by modiﬁcation of DRM structure in CF
inﬂammatory response.
5. Conclusion
In conclusion, our data further support the role of GBA2 in
inﬂammatory response occurring in CF bronchial epithelial
cells. In addition, we highlight the role of GBA2 in the
proinﬂammatory state occurring in CF bronchial epithelial
cells. We demonstrated that P. aeruginosa infection in CF
bronchial epithelial cells causes signiﬁcant changes in SL
and protein composition within speciﬁc membrane areas
involved in cell signaling regulation.
The structural modiﬁcation of these signaling platforms
may be involved in regulating the inﬂammatory response
in CF.
Finally, we believe that the identiﬁcation of speciﬁc SL
playing an active role in inﬂammatory response of CF cells
could pave the way to future therapeutic strategies for
treatment of inﬂammation in CF. However, further studies,
comprising in vivo validation, will be necessary to unravel
the involvement of the SL in the signaling cascade responsi-
ble for the regulation of inﬂammatory response in CF.
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